Letetresgene Autoleucel

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** Human autologous T-lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, letetresgene autoleucel specifically target and bind to NY-ESO-1/LAGE-1-overexpressing tumor cells. This may result in a cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1/LAGE-1-positive cancer cells. NY-ESO-1 and LAGE-1, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types.

**Synonyms:** - Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794 - Autologous T-Cells Expressing Enhanced TCRs Specific for NY-ESO-1/LAGE-1a GSK3377794 - Genetically Engineered NY-ESO-1 Specific [c259] T Cells GSK3377794 - Genetically Engineered NY-ESO-1/LAGE-1 Specific (c259) T Cells GSK3377794 - LETETRESGENE AUTOLEUCEL - NY-ESO-1c259 T Cells GSK3377794